Capitainer collaborates with Timothy Garrett Lab to accelerate method development for implementation of Capitainer’s qDBS sampling
Swedish medtech start-up Capitainer has entered a collaboration agreement with Timothy J. Garrett Laboratory, College of Medicine, University of Florida. Dr Tim Garrett is one of the leading experts and an authority in the US when it comes to applying mass spectrometry within the area of metabolomics and its clinical applications.
rate method development and pave the way for broader use of the qDBS (quantitative dried blood spot sampling) technology in clinical diagnosis. Capitainer has shown to have a superior product for self-sampling with excellent usability and volumetric accuracy and precision. However, there is a shortage of clinical laboratories and methods for microsamples collected at home, and the collaboration will accelerate the development of necessary laboratory tools.
“I’m excited about developing precision diagnostics that will enable future health care and look forward to this collaborative effort,” said Dr Garrett, an associate professor in the university’s Department of Pathology, Immunology and Laboratory Medicine. “Our success would mean a changed landscape for medical diagnostics.”
In the collaboration, Dr Donald H. Chace, Capitainer’s representative for North America will also bring his wealth of experience when it comes to analysing dried blood spot, covering Neonatology, Clinical Chemistry, Newborn Screening, Mass Spectrometry and Forensic Science as well as his lab’s resources to the table. This, combined with Dr Garrett’s access to a network of clinics for collaboration will, Capitainer believes, create the ideal foundation for new testing method development and validation within clinical diagnostics.
Over the last two years, Capitainer’s qDBS-sampling technology has been validated in real world population studies. No less than 97% of the cards sent back by regular mail to the lab met the approved quality standard for analysis. Additionally, in a major study published recently in Clinica Chimica Acta on the advantages of volumetric microsampling DBS devices in monitoring of patients with phenylketonuria (PKU), demonstrated conclusively the superiority of Capitainer’s solution over conventional cards and competition. See: https://www.sciencedirect.com/science/article/pii/S0009898122012566
Captainer AB is a Swedish medtech company founded in 2016. The company is developing intelligent solutions for Dried Blood and Plasma Spot sampling
with the market’s best volume accuracy serving several market segments, including Therapeutic Drug Monitoring, Biomarkers, Drug Development and Drugs of Abuse and Doping. By using a combination of paper- and polymer microfluidics the precision and accuracy of metering of capillary blood is on par with that of a standard displacement pipette. Thus, the technology enables more convenient solutions for patients’ home sampling ensuring more reliable test results for healthcare and other providers of tests based on blood or plasma.
